Research Article| Volume 310, ISSUE 1-2, P2-3, November 15, 2011

Is there a need to redefine Parkinson's disease?

Published:August 17, 2011DOI:


      Parkinson's disease (PD) has initially been described as a clinical syndrome, although the exact definition has changed over the past centuries. The inclusion of the pathological changes added another level of complexity, with Lewy bodies, synuclein deposits and neuronal loss in the substantia nigra being used alternatively. A third level of complexity was added with the recognition of genetic mutations resulting in parkinsonism, sometimes with and sometimes without Lewy body deposition, and the identification of frequent additional important pre-motor manifestations.
      These different points of view on the definition of PD have important implications on the study of the etiology and even the therapy of PD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Parkinson J.
        Essay on the Shaking Palsy.
        Sherwood, Neely and Jones, London1817
        • Poskanzer D.C.
        • Schwab R.S.
        Studies in the epidemiology of Parkinson's disease predicting its disappearance as a major clinical entity by 1980.
        Trans Am Neurol Assoc. 1961; 86: 234-235
        • Hughes A.J.
        • Daniel S.E.
        • Kilford L.
        • Lees A.J.
        Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
        J Neurol Neurosurg Psychiatry. 1992; 55: 181-184
        • Korczyn A.D.
        Autonomic nervous system dysfunction in Parkinson's disease.
        in: Calne D.B. Parkinsonism and Aging. Raven Press, N.Y1989: 219-221
        • Rascol O.
        • Brooks D.J.
        • Korczyn A.D.
        • De Deyn P.P.
        • Clarke C.E.
        • Lang A.E.
        A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group.
        N Engl J Med. 2000; 342: 1484-1491
        • Polymeropoulos M.H.
        • Lavedan C.
        • Leroy E.
        • et al.
        Mutation in the a-synuclein gene identified in families with Parkinson's disease.
        Science. 1997; 276: 2045-2047
        • Korczyn A.D.
        • Gurevich T.
        Parkinson's disease: before the motor symptoms and beyond.
        J Neurol Sci. 2010; 289: 2-6
        • Korczyn A.D.
        Autonomic nervous system dysfunction in Parkinson's disease.
        Adv Neurol. 1990; 53: 463-468
        • Braak H.
        • Del Tredici K.
        • Rub U.
        • de Vos R.A.I.
        • Jansen Steur E.N.H.
        • Braak E.
        Straging of brain pathology related to sporadic Parkinson's disease.
        Neurobiol Aging. 2003; 24: 197-211
        • Olanow W.C.
        Parkinson's disease, proteins, and prions: milestones.
        Mov Disord. 2011; 26: 1056-1071
        • Haugarvoll K.
        • Wszolek Z.K.
        Clinical features of LRRK2 parkinsonism.
        Parkinsonism Relat Disord. 2009; 15: S205-S208
        • Wider C.
        • Dickson D.W.
        • Wszolek Z.K.
        Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.
        Neurodegener Dis. 2010; 7: 175-179